Soligenix Inc (SNGX) Actualités

Soligenix to Present at Upcoming Investor Conferences

Soligenix to Present at Upcoming Investor Conferences PR Newswire PRINCETON, N.J., Jan. 16, 2025 PRINCETON...

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell...

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment PR Newswire PRINCETON, N.J., Dec...

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma PR...

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease PR...

Form 424B3 - Prospectus [Rule 424(b)(3)]